Open Access
Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya
Author(s) -
Laura C. Steinhardt,
Thomas L. Richie,
Reuben Yego,
Dorcas Akach,
Mary J. Hamel,
Julie Gutman,
Ryan E. Wiegand,
Elizabeth L Nzuu,
Allan Dungani,
Natasha Kc,
Tooba Murshedkar,
L. W. Preston Church,
B. Kim Lee Sim,
Eric R. James,
Yonas Abebe,
Simon Kariuki,
Aaron M. Samuels,
Kephas Otieno,
Tony Sang,
S. Patrick Kachur,
David Styers,
Kelly Schlessman,
Ginnie Abarbanell,
Stephen L. Hoffman,
Robert A. Seder,
Martina Oneko
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz925
Subject(s) - medicine , tolerability , adverse effect , placebo , vaccination , immunogenicity , plasmodium falciparum , randomized controlled trial , malaria vaccine , malaria , immunology , antibody , alternative medicine , pathology
The whole Plasmodium falciparum sporozoite (PfSPZ) vaccine is being evaluated for malaria prevention. The vaccine is administered intravenously for maximal efficacy. Direct venous inoculation (DVI) with PfSPZ vaccine has been safe, tolerable, and feasible in adults, but safety data for children and infants are limited.